EUVIMEDOpdag EUVIMED
Open access

Long‐Term Chronic Lung Allograft Dysfunction‐Free Survival Following Lung Transplant in the Presence of Donor‐Specific Antibodies

Benjamin Grobman iD, Andrew M Courtwright, Melissa Yeung, Selvin Jacob, Stefi Lee, Adil Sheikh, Mohamed Keshk, Amy Hackman, Anthony Coppolino, John Dunning, Nirmal Sharma, Hilary J Goldberg

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70241 ↗

At a glance

Journal article in Clinical Transplantation, 2025. Written by Benjamin Grobman and 11 co-authors. Institution: Harvard Medical School, Boston, Massachusetts, USA. Major MEDLINE topics: Lung Transplantation, Isoantibodies, Graft Rejection, Tissue Donors. 18 references. The full text is freely available in PubMed Central. Funded by: NHLBI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Highly sensitized patients with advanced lung disease, who are more often Black and Hispanic women, are at increased risk for waitlist death. In 2012, we implemented a protocol to cross any pre‐transplant donor‐specific antibody (DSA), so long as a prospective complement‐dependent cytotoxicity (CDC) crossmatch was negative. We report long‐term outcomes, including overall survival and chronic lung allograft dysfunction (CLAD)‐free survival.

Methods

This was a single‐institution retrospective cohort study of lung transplant recipients between October 1, 2012–December 31, 2022. We compared overall retransplant‐free survival and CLAD‐free survival between recipients with and without pre‐formed DSA. Secondary outcomes included freedom from acute cellular rejection (ACR) and antibody‐mediated rejection (AMR).

Results

The study cohort included 427 recipients with a median duration of follow‐up of 4.3 years (IQR = 2.1–6.9). Thirty‐three (7.7%) recipients had pre‐transplant DSA with a peak historical mean fluorescence intensity (MFI) of 4200 (IQR = 3000–6600, total range 2100–23 000). The median number of DSA per patient was 1 (IQR = 1–2, total range 1–8). There was no difference in adjusted overall survival between recipients with and without pre‐formed DSA (HR = 1.39, 95% CI = 0.82–2.36, p = 0.22) or adjusted CLAD‐free survival between recipients with and without pre‐formed DSA (HR = 1.07, 95% CI = 0.65–1.75, p = 0.79). Recipients with pre‐formed DSA did not have increased adjusted hazard of ACR (HR = 0.71, 95% CI = 0.29–1.75, p = 0.45) but did have increased adjusted hazard of AMR (HR = 5.02, 95% CI = 2.11–11.95, p < 0.001).

Conclusions

In this moderately‐sized cohort, a protocol of accepting donor offers for lung transplant candidates with pre‐formed DSA but negative CDC crossmatch was not associated with worse overall or CLAD‐free survival, within the limitations of the sample size.

Subjects

MeSH terms (MEDLINE)

Lung TransplantationIsoantibodiesGraft RejectionTissue DonorsPrimary Graft DysfunctionPostoperative ComplicationsHumansFemaleMaleRetrospective StudiesMiddle AgedFollow-Up StudiesPrognosisSurvival RateGraft SurvivalRisk FactorsAdultChronic DiseaseAllografts

Author keywords

clinical decision‐makingcrossmatchsensitization

Substances

Isoantibodies

Authors and institutions

  • Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Tissue Typing Lab, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID profiles: Benjamin Grobman

Funding

  • NHLBI NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Grobman, B., Courtwright, A. M., Yeung, M., Jacob, S., Lee, S., Sheikh, A., Keshk, M., Hackman, A., Coppolino, A., Dunning, J., Sharma, N., & Goldberg, H. J. (2025). Long‐Term Chronic Lung Allograft Dysfunction‐Free Survival Following Lung Transplant in the Presence of Donor‐Specific Antibodies. Clinical Transplantation. https://doi.org/10.1111/ctr.70241

Vancouver

Grobman B, Courtwright AM, Yeung M, Jacob S, Lee S, Sheikh A, et al. Long‐Term Chronic Lung Allograft Dysfunction‐Free Survival Following Lung Transplant in the Presence of Donor‐Specific Antibodies. Clinical Transplantation. 2025. doi:10.1111/ctr.70241

BibTeX
@article{Grobman2025,
  author = {Grobman, Benjamin and Courtwright, Andrew M and Yeung, Melissa and Jacob, Selvin and Lee, Stefi and Sheikh, Adil and Keshk, Mohamed and Hackman, Amy and Coppolino, Anthony and Dunning, John and Sharma, Nirmal and Goldberg, Hilary J},
  title = {Long‐Term Chronic Lung Allograft Dysfunction‐Free Survival Following Lung Transplant in the Presence of Donor‐Specific Antibodies},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70241}
}
Start for free →